ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.677,87
-0,45%
S&P 500
5.306,04
0,02%
Dow Jones
38.852,86
-0,55%
Euro vs US Dollar
1,0853
-0,01%
Bitcoin
68.240,22
-0,07%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Genprex Inc (GNPX)

  7. Genprex Inc (GNPX) News

GNPX

Genprex (GNPX)

Genprex Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:GNPX
DatumZeitQuelleÜberschriftSymbolFirma
20/05/202422h35Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GNPXGenprex Inc
15/05/202422h15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GNPXGenprex Inc
14/05/202414h31PR Newswire (US)Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerNASDAQ:GNPXGenprex Inc
13/05/202414h31PR Newswire (US)Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of DirectorsNASDAQ:GNPXGenprex Inc
09/05/202414h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
09/05/202400h08PR Newswire (US)Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney VarnerNASDAQ:GNPXGenprex Inc
01/05/202414h31PR Newswire (US)Genprex to Present and Participate at Upcoming May Investor and Industry ConferencesNASDAQ:GNPXGenprex Inc
09/04/202414h31PR Newswire (US)Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual MeetingNASDAQ:GNPXGenprex Inc
03/04/202414h31PR Newswire (US)Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerNASDAQ:GNPXGenprex Inc
02/04/202414h31PR Newswire (US)Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery SystemNASDAQ:GNPXGenprex Inc
22/03/202421h10PR Newswire (US)Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:GNPXGenprex Inc
19/03/202418h24PR Newswire (US)Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:GNPXGenprex Inc
19/03/202413h36PR Newswire (US)Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:GNPXGenprex Inc
12/03/202414h01PR Newswire (US)Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat CancersNASDAQ:GNPXGenprex Inc
06/03/202415h18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
06/03/202414h30PR Newswire (US)Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual MeetingNASDAQ:GNPXGenprex Inc
26/02/202414h45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
21/02/202422h34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GNPXGenprex Inc
21/02/202422h32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GNPXGenprex Inc
21/02/202422h28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GNPXGenprex Inc
14/02/202420h14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GNPXGenprex Inc
07/02/202414h15PR Newswire (US)Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research CollaboratorsNASDAQ:GNPXGenprex Inc
06/02/202413h30PR Newswire (US)Genprex to Present at Upcoming BIO CEO & Investor ConferenceNASDAQ:GNPXGenprex Inc
05/02/202414h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
05/02/202413h30PR Newswire (US)Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung CancerNASDAQ:GNPXGenprex Inc
02/02/202413h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
31/01/202415h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
31/01/202414h42PR Newswire (US)Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024NASDAQ:GNPXGenprex Inc
05/01/202422h17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GNPXGenprex Inc
05/01/202413h00PR Newswire (US)Genprex Provides Business Update and Outlook for 2024NASDAQ:GNPXGenprex Inc
 Showing the most relevant articles for your search:NASDAQ:GNPX

Kürzlich von Ihnen besucht

NYSE
IT
Gartner
NASDAQ
QLTY
LSE
BONH
Bonhill
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten